SC-57461A

• Description:

  SC-57461A is a potent, orally active, nonpeptide, and selective inhibitor of Leukotriene A4 (LTA4) hydrolase with IC50s of 2.5 nM, 3 nM, and 23 nM for recombinant human, mouse, and rat LTA4 hydrolase, respectively[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  Aminopeptidase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/sc-57461a.html

• Concentration:

  10mM

• Purity:

  99.93

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C (O) CCN (C) CCCOC1=CC=C (CC2=CC=CC=C2) C=C1.[H]Cl

• Molecular Formula:

  C20H26ClNO3

• Molecular Weight:

  363.88

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Leslie J Askonas, et al. Pharmacological characterization of SC-57461A (3-[methyl[3-[4- (phenylmethyl) phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A (4) hydrolase I: in vitro studies. J Pharmacol Exp Ther. 2002 Feb;300 (2) :577-82.|[2]T D Penning. Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents. Curr Pharm Des. 2001 Feb;7 (3) :163-79.|[3]James F Kachur, et al. Pharmacological characterization of SC-57461A (3-[methyl[3-[4- (phenylmethyl) phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A (4) hydrolase II: in vivo studies. J Pharmacol Exp Ther. 2002 Feb;300 (2) :583-7.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  423169-68-0